Brief: Xbiotech Announces Completion And Positive Interim Findings For Initial Cohort In Bermekimab Pilot Study In Atopic Dermatitis
13/09/2018 13:12
Sept 13 (Reuters) - XBiotech Inc XBIT.O :
* XBIOTECH ANNOUNCES COMPLETION AND POSITIVE INTERIM
FINDINGS FOR
INITIAL COHORT IN BERMEKIMAB PILOT STUDY IN ATOPIC DERMATITIS
* XBIOTECH - STATISTICALLY SIGNIFICANT IMPROVEMENTS IN
ATOPIC
DERMATITIS PATIENTS TREATED WITH LOW DOSE, SHORT COURSE OF
BERMEKIMAB
* XBIOTECH INC - 200MG SUBCUTANEOUS INJECTIONS WERE WELL
TOLERATED
IN COHORT
* XBIOTECH INC - STUDY WILL NOW BEGIN ENROLLMENT OF 20
PATIENTS TO
RECEIVE 400MG WEEKLY DOSES OVER AN 8 WEEK TREATMENT PERIOD
Source text for Eikon: ID:nGNE18Bnlk
Further company coverage: XBIT.O
((Briefs@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke